Leo E, Schlegel P G, Lindemann A
University of Freiburg Medical Center, Department of Internal Medicine I (Hematology-Oncology), Germany.
J Neurooncol. 1997 Apr;32(2):149-54. doi: 10.1023/a:1005721510659.
The treatment of extraneural metastatic medulloblastoma is mainly a domain of chemotherapy. Although previous results were promising, the overall poor prognosis high relapse rates and the still unknown ideal combination of chemotherapeutic agents leave many questions open. In this study, the effectiveness of previously used chemotherapeutic agents for the treatment of metastatic medulloblastoma is reviewed, and the effectiveness and complexity of emerging new treatment strategies including high-dose chemotherapy with bone marrow and peripheral blood stem-cell transplantation are discussed. Furthermore, we describe a case of bone-metastasized recurrent medulloblastoma with the longest remission ever reported (120 months) after regimens containing doxorubicine, vincristine, cyclophosphamide (ACO-protocol) [1, 2] and methotrexate. When relapse with bone and bone marrow infiltration occurred, a second chemotherapeutically induced complete remission was achieved. High-dose-chemotherapy with autologous peripheral blood stem-cell transplantation was used as a consolidating regimen. Complete remission has persisted for over 15 months now.
神经外转移性髓母细胞瘤的治疗主要是化疗领域。尽管先前的结果很有希望,但总体预后较差、高复发率以及化疗药物的理想组合仍不明确,这些都留下了许多有待解决的问题。在本研究中,回顾了先前用于治疗转移性髓母细胞瘤的化疗药物的有效性,并讨论了包括高剂量化疗联合骨髓和外周血干细胞移植在内的新兴新治疗策略的有效性和复杂性。此外,我们描述了一例骨转移复发性髓母细胞瘤病例,该病例在接受含有阿霉素、长春新碱、环磷酰胺(ACO方案)[1,2]和甲氨蝶呤的治疗方案后,获得了有报道以来最长的缓解期(120个月)。当出现骨和骨髓浸润复发时,通过化疗再次诱导实现了完全缓解。采用高剂量化疗联合自体外周血干细胞移植作为巩固治疗方案。目前完全缓解已持续超过15个月。